VRAY.Q Stock Overview
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ViewRay, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$4.96 |
| 52 Week Low | US$0.000001 |
| Beta | 0.76 |
| 1 Month Change | -98.88% |
| 3 Month Change | -99.57% |
| 1 Year Change | -100.00% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Market Cool On ViewRay, Inc.'s (NASDAQ:VRAY) Revenues Pushing Shares 63% Lower
Apr 17
Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?
Dec 24ViewRay MRI-guided radiation therapy selected by SUNY upstate cancer center
Oct 06ViewRay's MRI-guided radiation therapy gets approval in China
Sep 07ViewRay MRI-guided radiation therapy selected by VA Houston Healthcare System
Aug 23ViewRay: Insider Buying In This $3 Stock
May 15Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?
Apr 22Is ViewRay (NASDAQ:VRAY) Using Debt Sensibly?
Aug 09ViewRay, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 08Read This Before Selling ViewRay, Inc. (NASDAQ:VRAY) Shares
Mar 03How Many ViewRay, Inc. (NASDAQ:VRAY) Shares Do Institutions Own?
Jan 27
ViewRay rallies premarket on Q4 preliminary revenue
Jan 04ViewRay's (NASDAQ:VRAY) Stock Price Has Reduced 56% In The Past Three Years
Dec 22ViewRay +10.6% on CEO acquiring shares
Nov 12Shareholder Returns
| VRAY.Q | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | 1.2% |
| 1Y | -100.0% | -0.5% | 24.9% |
Return vs Industry: VRAY.Q underperformed the US Medical Equipment industry which returned -1.8% over the past year.
Return vs Market: VRAY.Q underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| VRAY.Q volatility | |
|---|---|
| VRAY.Q Average Weekly Movement | 2,748.1% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VRAY.Q's share price has been volatile over the past 3 months.
Volatility Over Time: VRAY.Q's weekly volatility has increased from 1401% to 2748% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 295 | Paul Ziegler | www.viewray.com |
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors.
ViewRay, Inc. Fundamentals Summary
| VRAY.Q fundamental statistics | |
|---|---|
| Market cap | US$18.34k |
| Earnings (TTM) | -US$110.41m |
| Revenue (TTM) | US$105.86m |
0.0x
P/S Ratio0.0x
P/E RatioIs VRAY.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRAY.Q income statement (TTM) | |
|---|---|
| Revenue | US$105.86m |
| Cost of Revenue | US$97.34m |
| Gross Profit | US$8.52m |
| Other Expenses | US$118.94m |
| Earnings | -US$110.41m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.60 |
| Gross Margin | 8.05% |
| Net Profit Margin | -104.30% |
| Debt/Equity Ratio | 140.7% |
How did VRAY.Q perform over the long term?
See historical performance and comparison